Hongxuan Wang, Lei Liu, Xuhui Zhou, Yanzhong Guan, Yanfei Li, Peiyun Chen, Ranran Duan, Weibian Yang, Xiaoming Rong, Chengji Wu, Jianzhong Yang, Mei Yang, Yanjie Jia, Jian Hu, Xiaofeng Zhu, Ying Peng
AIMS: To measure the therapeutic effect of an anti-oxidant, edaravone (EDV), or neurotrophic treatment with nerve growth factor (NGF) as an add-on treatment for alcohol-related brain damage (ARBD). DESIGN: Multi-centre, randomised, single-blinded, comparative clinical trial. SETTING AND PARTICIPANTS: One hundred and twenty-two inpatients recruited from seven hospitals in different regions of China, all diagnosed with ARBD and aged 18 to 65 years old; among them, only two were female...
December 4, 2023: Addiction